证券日报网讯德展健康（000813）11月11日在互动平台回答投资者提问时表示，公司始终高度重视市值 管理工作，一方面通过制定《市值管理制度》等构建规范管理体系，充分合规运用市值管理工具，加强 与各市场主体的沟通交流，传递公司价值；另一方面积极做好各项经营工作，以提高公司质量、提升内 在价值、提升股东回报能力为基础，科学统筹稳步推进市值管理工作。 ...

Core Viewpoint - The company, Dezhan Health (000813), has indicated that it has explored the use of rose extract in its innovative drug discovery research, but has not yet officially initiated related studies [1] Group 1 - The company has engaged in exploratory research involving rose extract [1] - There is no formal project established for further research on rose extract at this time [1]

Core Insights - The company is developing the Hainan Decheng International Medical and Health Complex project, which is not currently covered by the "Special Medical" policy but benefits from the general policies of the Hainan Free Trade Port [1][2] - The project has been recognized as a major project in Hainan Province for 2025 and has signed a strategic cooperation framework agreement with China General Technology Group's subsidiary, aiming to enhance the company's health service capabilities [2][3] - The company reported a revenue of 278 million yuan for the first nine months of 2025, a year-on-year decrease of 21.71%, and a net loss of 64 million yuan, with losses expanding by 1493.85% compared to the previous year [1] Project Details - The Hainan Decheng International Medical and Health Complex project includes a secondary rehabilitation hospital with a construction area of approximately 15,500 square meters and a total of about 182 beds [2] - The project has a total investment of approximately 489 million yuan and a total construction area of about 71,828 square meters [2] - The project aims to create an international health complex that integrates medical, research, tourism, and wellness services, leveraging high-quality global medical resources [3]

Core Viewpoint - Dezheng Health's stock price has experienced fluctuations, with a year-to-date increase of 39.30%, but a recent decline in trading performance [1][2]. Group 1: Stock Performance - On November 11, Dezheng Health's stock fell by 2.02%, trading at 4.36 CNY per share, with a total market capitalization of 9.143 billion CNY [1]. - The stock has seen a net outflow of 21.3992 million CNY in principal funds, with significant selling pressure observed [1]. - Year-to-date, the stock has risen by 39.30%, but has seen a slight decline of 1.13% over the last five trading days [1]. Group 2: Financial Performance - For the period from January to September 2025, Dezheng Health reported a revenue of 278 million CNY, a year-on-year decrease of 21.71%, and a net profit attributable to shareholders of -61.0254 million CNY, a significant decline of 854.37% [2]. - The company has not distributed any dividends in the last three years, with a total payout of 470 million CNY since its A-share listing [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders decreased to 57,600, with an average of 36,404 circulating shares per person, reflecting a slight decline [2]. - The Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders [3].

Core Viewpoint - The company is actively involved in the development of innovative drugs and has a significant partnership in the DNA immunotherapy field, specifically targeting HPV-related precancerous lesions [1] Group 1: Company Collaboration and Projects - The VGX-3100 project is a key collaboration between the company's subsidiary, Dongfang Lue, and Inovio, focusing on DNA immunotherapy for treating precancerous lesions caused by HPV [1] - Dongfang Lue holds exclusive rights for the development, production, and commercialization of the product in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan [1] Group 2: Company Holdings and Market Position - The company does not hold any shares in Inovio and has no mutual shareholding plans with them [1] - Currently, the company positions itself as a generic drug company but is actively pushing forward with the research and development of innovative drugs such as WYY and ZT [1]

Company Overview - Dezheng Health was established on January 1, 1981, and listed on the Shenzhen Stock Exchange on May 19, 1998. The company is headquartered in Urumqi, Xinjiang, with its office located in Beijing. It is a leading enterprise in the research and manufacturing of cardiovascular drugs in China, with its core product being Alet (Atorvastatin Calcium Tablets), which has both brand and technological advantages [1] Financial Performance - In Q3 2025, Dezheng Health achieved a revenue of 278 million yuan, ranking 93rd among 110 companies in the industry. The top company, Huadong Medicine, reported a revenue of 32.664 billion yuan, while the second, Fosun Pharma, reported 29.393 billion yuan. The industry average revenue was 280 million yuan, with a median of 83.8 million yuan [2] - The net profit for the same period was -88.5372 million yuan, ranking 91st in the industry. The leading company, Heng Rui Medicine, reported a net profit of 5.76 billion yuan, and Fosun Pharma reported 3.056 billion yuan. The industry average net profit was 299 million yuan, with a median of 78.2908 million yuan [2] Financial Ratios - As of Q3 2025, Dezheng Health's debt-to-asset ratio was 5.18%, up from 2.63% in the same period last year, significantly lower than the industry average of 35.26%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 55.57%, down from 61.46% in the previous year, slightly below the industry average of 57.17% [3] Leadership - The controlling shareholder of Dezheng Health is Xinjiang Kaidi Investment Co., Ltd., with the actual controller being the State-owned Assets Supervision and Administration Commission of the Xinjiang Uygur Autonomous Region. The chairman, Wei Zheming, born in November 1982, holds a master's degree in business administration and has extensive management and investment experience. He has held significant positions in various companies, including Tebian Electric Apparatus and Xinjiang Lianchuang Yongjin. The general manager, Liu Wei, born in January 1970, is a licensed pharmacist with a salary of 3.98 million yuan in 2024, unchanged from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders of Dezheng Health was 57,600, a decrease of 1.13% from the previous period. The average number of circulating A-shares held per household was 36,400, down by 2.03%. Additionally, as of the same date, Hong Kong Central Clearing Limited exited the list of the top ten circulating shareholders [5]

Market Overview - On October 31, the Xinjiang state-owned enterprise reform sector rose by 0.94% compared to the previous trading day, with Dezhang Health leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Stock Performance - Dezhang Health (000813) closed at 4.38, up 5.29% with a trading volume of 1.1741 million shares and a turnover of 511 million yuan [1] - Tianfu Energy (600509) closed at 8.58, up 4.00% with a trading volume of 660,100 shares and a turnover of 555 million yuan [1] - Xinjiang Communications Construction (002941) closed at 18.92, up 2.83% with a trading volume of 649,000 shares and a turnover of 1.233 billion yuan [1] - Other notable stocks include Qingsong Jianhua (600425) up 2.17%, Xiyu Tourism (300859) up 1.50%, and ST Zhongji (000972) up 1.36% [1] Capital Flow - The Xinjiang state-owned enterprise reform sector saw a net inflow of 59.4644 million yuan from main funds, while retail funds experienced a net outflow of 44.876 million yuan [2] - The main funds showed a significant interest in Tianfu Energy and Xinjiang Communications Construction, with net inflows of 97.0517 million yuan and 68.8371 million yuan respectively [3] - Retail investors showed a net outflow from several stocks, including Tianfu Energy and Xinjiang Communications Construction, indicating a shift in investor sentiment [3]

Market Performance - The Xinjiang state-owned enterprise reform sector increased by 0.6% compared to the previous trading day, with Baodi Mining leading the gains [1] - The Shanghai Composite Index closed at 4016.33, up by 0.7%, while the Shenzhen Component Index closed at 13691.38, up by 1.95% [1] Individual Stock Performance - Baodi Mining (601121) closed at 7.37, with a rise of 2.65% and a trading volume of 216,000 shares, amounting to a transaction value of 158 million [1] - Western Gold (601069) closed at 28.05, up by 1.96%, with a trading volume of 183,300 shares and a transaction value of 510 million [1] - Lide New Energy (001258) closed at 8.33, also up by 1.96%, with a trading volume of 580,400 shares and a transaction value of 479 million [1] - Xinjiang Communications Construction (002941) closed at 18.86, up by 1.89%, with a trading volume of 1,619,300 shares and a transaction value of 1.144 billion [1] Capital Flow Analysis - The Xinjiang state-owned enterprise reform sector experienced a net outflow of 97.53 million from institutional investors, while retail investors saw a net inflow of 65.44 million [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are actively buying [2] Detailed Capital Flow by Stock - Western Gold (601069) had a net outflow of 30.21 million from institutional investors, while retail investors contributed a net inflow of 3.51 million [3] - Baodi Mining (601121) saw a net inflow of 22.37 million from institutional investors, but a net outflow of 21.32 million from retail investors [3] - Lide New Energy (001258) had a net inflow of 18.61 million from institutional investors, with retail investors also contributing a net inflow of 22.17 million [3]

Core Viewpoint - The company, 德展大健康股份有限公司, has released its third-quarter financial report for 2025, ensuring the accuracy and completeness of the information disclosed [1][2][9]. Financial Data Summary - The third-quarter financial report has not been audited [8]. - The company does not require retrospective adjustments or restatements of previous accounting data [3]. - There are no non-recurring profit and loss items applicable for this quarter [3][4]. Board Meeting Summary - The company's ninth board meeting was held on October 24, 2025, with all nine directors present, confirming compliance with legal and procedural requirements [10][12]. - The board approved the third-quarter report with unanimous consent [12][13].

Group 1 - The core viewpoint of the news is that 德展健康 (Dezhan Health) reported a significant decline in revenue and incurred a net loss in its third-quarter performance for 2025 [1] - The company's revenue for the first three quarters of 2025 was approximately 278 million yuan, representing a year-on-year decrease of 21.71% [1] - The net profit attributable to shareholders was a loss of approximately 61.03 million yuan, with a basic earnings per share loss of 0.0288 yuan [1] Group 2 - As of the report, 德展健康 has a market capitalization of 8.7 billion yuan [2] - The news highlights the broader context of the biopharmaceutical market, noting that China’s innovative drugs have generated 80 billion US dollars in overseas licensing this year [2] - There is a contrast drawn between the hot secondary market for biopharmaceuticals and the cooling fundraising environment in the primary market [2]